Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
Chng, W-J, Goldschmidt, H, Dimopoulos, M A, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-MarLanguage:
english
Journal:
Leukemia
DOI:
10.1038/leu.2016.390
Date:
December, 2016
File:
PDF, 1.84 MB
english, 2016